Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants

NCT01590316 is registered in ClinicalTrials.gov with Gorm Greisen as lead sponsor.

NCT NCT01590316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01590316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants
Lead sponsor
Gorm Greisen
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2012
Completion date
March 31, 2018
Enrollment
165 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain injuries, infant, premature